China Reports More Than 7000 Chikungunya Cases: Symptoms, Risk Factors, Complications And More
For the unversed, chikungunya is a viral vector-borne disease. It is transmitted to humans through the bite of infected mosquitoes, primarily the Aedes aegypti and Aedes albopictus species. The virus doesn't spread from person to person through close contact, however, blood transmission may be possible.
What are the symptoms of chikungunya?
Chikungunya is characterised by a sudden onset of fever and severe joint pain. The incubation period is typically 3-7 days.
High fever
Severe joint pain and swelling
Muscle pain
Headache
Fatigue
Rash
Severe joint pain is one of the distinct symptoms of chikungunya, which may last for weeks, months and even years. Older adults or those with pre-existing conditions are also likely to experience severe joint pain, especially during extreme weather conditions. Other symptoms are generally self-limiting and improve within a week.
What are the treatment options for chikungunya?
Chikungunya treatment mainly focuses on relieving symptoms. Anti-inflammatory medicines and pain killers are usually used to manage fever and joint and muscle pain. Rest and adequate hydration also assist in quick recovery.
Is chikungunya fatal?
Chikungunya is rarely fatal. However, the elderly, newborns or individuals with pre-existing health conditions remain at a higher risk of severe complications.
Most symptoms are generally self-limiting and last for 2-3 days. The disease is characterised by an abrupt onset of fever, which is frequently accompanied by joint pain. Other common signs and symptoms include muscle pain, headache, nausea, fatigue and rash.
How to prevent chikungunya
Chikungunya prevention involves reducing mosquito exposure and controlling mosquito populations. Effective strategies include:
Use insect repellent containing DEET or eucalyptus oil, especially when outdoors
Wear long-sleeved clothes and full-length pants to minimise skin exposure
Use mosquito nets while sleeping, especially in areas where chikungunya is prevalent
Eliminate standing water, as this is where mosquitoes breed
Install screens on windows and doors to keep mosquitoes out
Stay indoors during peak hours when mosquitoes that transmit chikungunya are most active, especially at dawn and dusk.
According to the World Health Organisation, the chikungunya virus was first identified in the United Republic of Tanzania in 1952 and subsequently in other countries in Africa and Asia. Urban outbreaks were first recorded in Thailand in 1967 and in India in the 1970s. Currently, there are two chikungunya vaccines available in the United States: IXCHIQ (a live-attenuated vaccine and VIMKUNYA (a virus-like particle vaccine).
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Economic Times
2 hours ago
- Economic Times
Ditch your glasses - breakthrough eye drops approved by FDA to fix your near vision instantly
Vizz, a new FDA-approved eye drop, offers adults with age related near vision loss (presbyopia) a daily, non-surgical solution. Developed by Lenz Therapeutics, it works by gently shrinking the pupil to help focus on nearby objects. Backed by clinical trials, Vizz acts within 30 minutes and lasts up to 10 hours, offering freedom from reading glasses for millions. Tired of too many ads? Remove Ads Strong clinical results with minimal side effects A modern alternative for aging eyes Tired of too many ads? Remove Ads FAQs: In a major medical breakthrough, the U.S. Food and Drug Administration has approved Vizz , a once daily eye drop that helps improve near vision without the need for reading glasses. Created by Lenz Therapeutics , Vizz is the first eye drop to use aceclidine, a compound that temporarily reduces pupil size to sharpen close up eye drop works by creating a mild "pinhole effect" that extends the eye's depth of focus, improving the ability to see things up close. Vizz is fast acting, with noticeable improvement in vision within 30 minutes, and the benefits can last for up to 10 hours with just one drop a was approved after being tested in three major Phase 3 trials CLARITY 1, 2, and 3. These studies involved hundreds of participants over several weeks and months. Results showed that a majority of users gained a three-line improvement in near vision on a standard eye chart, a strong indicator of more reassuring, the safety profile was excellent. No serious side effects were reported. A small number of users experienced mild symptoms like eye irritation, headache, or dim vision, but these effects were temporary and resolved without treatment. Importantly, Vizz did not negatively affect distance vision, making it practical for everyday could be a game changer for the estimated 128 million Americans living with presbyopia . Rather than relying on glasses or surgical options, patients now have access to a non-invasive, convenient treatment they can use daily. The drops are expected to be available in the U.S. by late 2025, starting with sample distributions in doctors' approval marks a turning point in eye care innovation. With its fast results, strong safety data, and ease of use, Vizz offers new hope to people who want to regain near vision clarity and reduce their dependence on corrective lenses.A1. Presbyopia is a common condition where the eye's lens loses flexibility, making it hard to focus on close-up objects. It typically starts after the age of 40.A2. As we age, the lens inside the eye becomes less flexible. This makes it harder for the eye to adjust and focus on close objects.
New Indian Express
3 hours ago
- New Indian Express
Urgently scale-up research and innovation to end TB: WHO
NEW DELHI: The World Health Organisation (WHO) has called for an urgent scale-up of research, innovation, and collaboration to accelerate momentum towards ending tuberculosis in the WHO South-East Asia Region, which continues to bear nearly half of the global TB burden, accounting for the highest share of cases and deaths worldwide. 'In our Region alone, nearly 5 million people developed TB and close to 600,000 died from the disease in 2023,' said Dr Catharina Boehme, Officer-in-Charge, WHO South-East Asia Region. Calling for urgent action, she said, 'Achieving the ambitious targets in the WHO End TB Strategy requires collaboration to accelerate research and innovation. It requires the adoption and use of new tools, technologies, and drugs. Ensuring timely and equitable access to these innovations remains critical to achieving impacts at scale, leaving no one behind.' While the Region, which includes India, recorded a significant increase in TB case notifications in 2023 - signalling recovery after COVID-19-related setbacks - progress remains insufficient to meet the End TB Strategy targets aligned with the Sustainable Development Goals, which call for a 90 per cent reduction in TB deaths and an 80 per cent reduction in incidence by 2030, compared to 2015 levels. India aims to eliminate TB by 2025, ahead of the global target.
Mint
4 hours ago
- Mint
What Robert F. Kennedy junior means for American health?
As in most marriages of convenience, Donald Trump and Robert F. Kennedy junior make unusual bedfellows. One enjoys junk food, hates exercise and loves oil. The other talks of clean food, getting America moving again and wants to eliminate oils of all sorts (from seed oil to Mr Trump's beloved 'liquid gold'). One has called the covid-19 vaccine a 'miracle', the other is a long-term vaccine sceptic. Yet on November 14th Mr Trump announced that Mr Kennedy was his pick for secretary of health and human services (HHS). Public-health leaders have responded with horror and disbelief. 'Robert F. Kennedy junior is not remotely qualified for the role,' said Dr Peter Lurie, president of the Centre for Science in Public Interest, a public-health watchdog, in a statement, adding that 'nominating an anti-vaxxer like Kennedy to HHS is like putting a Flat Earther at the head of NASA.' Industry types are similarly worried. Shares in vaccine-makers, such as Moderna and Pfizer, and biotech firms fell in response to the news. Read more of our coverage of America's presidential election The panic is understandable. Mr Kennedy has a long history of promoting debunked health theories and claims about vaccines, most damagingly about the risks of inoculating children. He has said that 'there's no vaccine that is safe and effective' and has advised parents not to follow guidance by the Centres for Disease Control and Prevention (CDC), one of the health agencies that could soon fall under his direction. He is a proponent of several unproven alternatives to mainstream medicine, ranging from the kooky but harmless to the actively dangerous. And he has promised to dismantle large parts of America's core public-health agencies—including the CDC, the Food and Drug Administration and the National Institutes of Health (NIH)—and purge them of the 'smothering cloud of corporate capture'. If he does make it into the job (he will have to survive confirmation by the Senate), what might that mean in practice? His Make America Healthy Again (MAHA) movement, which the Trump campaign embraced in the final phase of the election, gives clues to some of his public-health priorities. But surprisingly little is known about his approach to other big issues, such as drug-price negotiations or government-funded health-care programmes. 'I don't think anybody really knows what it means for Medicare and Medicaid,' says James Capretta, from the American Enterprise Institute, a think-tank. What is clear is that Mr Kennedy has radical ambitions and that Mr Trump, at least for now, has backed him fully. In his nomination statement, Mr Trump echoed Mr Kennedy's favourite talking points, writing that 'Americans have been crushed by the industrial food complex and drug companies who have engaged in deception, misinformation and disinformation when it comes to Public Health.' Mr Kennedy, he promised, would restore the government's health agencies to 'Gold Standard Scientific Research', end the chronic-disease epidemic, and 'Make America Great and Healthy Again'. Many fear that the opposite could happen. They worry that core public-health and research programmes will be shut down and replaced by pseudoscience. Those concerns are not unfounded. Mr Kennedy recently said that on the second day of the new administration, '600 people are going to walk into offices at NIH and 600 people are going to leave.' He has also suggested that half the NIH's budget be devoted to researching 'preventative, alternative and holistic' medicines. Although the likely deprioritisation of tackling infectious diseases is worrying, Mr Kennedy's mission to go after chronic disease in America is laudable. Nearly half the country is now pre-diabetic or diabetic and some of the methods he champions—such as eating healthy, pesticide-free food and exercising—are sensible. And Mr Kennedy's candid criticisms of Big Food and Big Pharma are a salutary counterweight to powerful vested interests that few dare to stand up to. One need not be a conspiracy theorist to see that their relationships with regulators that they help fund is, at the very least, complex. Yet precisely because of his bulldog attitude to industry, Mr Kennedy will probably run into trouble with Republicans in Congress, who have long relied on these sectors for support and may see his proposals as 'nanny state' and anti-business. Although several Republican senators took to social media to pledge their support (Josh Hawley of Missouri said it was a 'bad day for Big Pharma'), others reserved judgment. 'I look forward to learning more about his other policy positions and how they will support a conservative, pro-American agenda,' wrote Bill Cassidy, from Louisiana. If Mr Kennedy does become health secretary, the extent and duration of his power will depend on Mr Trump's continued tolerance for letting him 'go wild'. Unlike most of Mr Trump's loyalist cabinet picks, Mr Kennedy is a former rival and a recent—and no doubt conditional—MAGA convert. For now Mr Kennedy benefits from a boss who is not interested in health policy. This may change if Mr Trump is confronted with the type of public-health disaster that can't be ignored, as it happened with covid-19 in his first term. Or perhaps he will pull the plug once he realises that Mr Kennedy is after his—and his voters'—cheeseburgers. Just as Mr Kennedy's support for MAGA is conditional, so is Mr Trump's commitment to 'in sickness and in health'. Stay on top of American politics with The US in brief, our daily newsletter with fast analysis of the most important electoral stories, and Checks and Balance, a weekly note from our Lexington columnist that examines the state of American democracy and the issues that matter to voters.
